←
TwoOncDocs632 posts
TwoOncDocs avatar

TwoOncDocs

@TwoOncDocs

🩸 a podcast about heme/onc for health care providers | ☕️ short high yield episodes to supplement your board review resources | @SamArmstrongMD @DrKarineTawagi

◷ Joined June 2022▧ 77 Photos and videos
TwoOncDocs avatar
TwoOncDocs@TwoOncDocs·Aug 31

🤔 Heading to #ASH26? ⭐️ Join us for a complimentary in-person Hematology Board Review for fellows & anyone prepping for boards 🩸 📅 Friday, December 11, 2026 🕗 8:00 AM–12:00 PM CT 📍 420 Julia St., New Orleans, LA 🔗 Register: bit.ly/hemeboards

Post attachment
TwoOncDocs avatar
TwoOncDocs@TwoOncDocs·19h

GOOD LUCK to all taking heme & onc boards this week! We are back with localized #prostatecancer updates 💙 A 60M has unfavorable intermediate prostate cancer, and decides to undergo radiation ☢️ , what is the recommended course of ADT?

Karine Tawagi MD avatar
⟳ TwoOncDocs retweeted
Karine Tawagi MD@DrKarineTawagi·Nov 13

📣 FDA approval today for peri-op Durva/EV for cis-ineligible/declining + Durva only in adjuvant setting, very timely as we discuss MIBC regimens at #UromigosLIVE @Uromigost @OncoAlert Met EFS & OS ⁉️ can we use ctDNA/pCR to de-escalate adjuvant EV?

Post attachmentPost attachment

💫#VOLGA: Durva + EV in cis-ineligible, like #EV303 but NO adjuvant EV here ⬆️ 2-year EFS (HR 0.51), OS (HR 0.58) & pCR (45% vs 10%) Triplet arm OS not significant & ⬆️ tox Less robust #s then EVP but how much benefit does adjuvant EV add? Can we use ctDNA/pCR to ⬇️? #ESMO26

Post attachmentPost attachmentPost attachmentPost attachment
TwoOncDocs avatar
TwoOncDocs@TwoOncDocs·Nov 3

We released our cheat sheet of highest yield topics last week for ABIM exams coming up Nov 17&18! 🫁 Onc: GI 13.5% Breast 13.5% GU 12% Thoracic 11.5% Together, represent over 50% 🩸 Heme: Neoplasms make up 35% Prioritize leukemias, lymphomas, and plasma cell disorders GL! 🙏🏼

Karine Tawagi MD avatar
⟳ TwoOncDocs retweeted
Karine Tawagi MD@DrKarineTawagi·Oct 26

📣 another FDA approval in APMS ➡️ MANY in 2026 inc. pluvicto & capivasertib ➡️ now talazoparib/enza vs enza #TALAPRO3 for HRR-altered APMS (vs AMPLITUDE only BRCA2) ➡️ rPFS 77% vs 56% (HR 0.48) ⚠️ OS immature, G≥3 anemia 51%, 40% transfused; no docetaxel-triplet comparator

Post attachment
Karine Tawagi MD avatar
⟳ TwoOncDocs retweeted
Karine Tawagi MD@DrKarineTawagi·Oct 25

Incredible to see work on the very rare RCC subtypes: collecting duct & renal medullary CA at #ESMO26 #REPRINT trial testing EV + P 🎯 22% ORR & 55% DCR overall ➡️ moving to stage 2! Also very impt trials from @PavlosMsaouel in RMC on: ubamatamab, Sac-TMT, panitumumab…

Post attachmentPost attachmentPost attachmentPost attachment
Karine Tawagi MD avatar
⟳ TwoOncDocs retweeted
Karine Tawagi MD@DrKarineTawagi·Oct 24

💫#VOLGA: Durva + EV in cis-ineligible, like #EV303 but NO adjuvant EV here ⬆️ 2-year EFS (HR 0.51), OS (HR 0.58) & pCR (45% vs 10%) Triplet arm OS not significant & ⬆️ tox Less robust #s then EVP but how much benefit does adjuvant EV add? Can we use ctDNA/pCR to ⬇️? #ESMO26

Post attachmentPost attachmentPost attachmentPost attachment
Karine Tawagi MD avatar
⟳ TwoOncDocs retweeted
Karine Tawagi MD@DrKarineTawagi·Oct 24

Incredible cancer breakthrough #ESMO26 w/ new benchmark in melanoma & huge advances for all future personalized tx that could extend to other cancers 🌟 Ph3 Intismeran autogene mRNA vaccine improved RFS by 42% w/ Pembro vs Pembro alone, distant mets reduced by 38%, similar AEs

Post attachmentPost attachmentPost attachmentPost attachment
Karine Tawagi MD avatar
⟳ TwoOncDocs retweeted
Karine Tawagi MD@DrKarineTawagi·Oct 24

🔥 full house before #ESMO26 Presidential: 🔹#INTerpath001: Intismeran autogene + pembro vs pembro in resected melanoma 🔹#VOLGA: Periop durva ± treme + EV in MIBC 🔹#DeLLphi-305: Tarlatamab + durva vs durva as 1L maintenance in ES-SCLC 🔹Daro + ADT + RT in very high-risk PCa

Post attachment
Sakditad “Tew” Saowapa, MD avatar
⟳ TwoOncDocs retweeted
Sakditad “Tew” Saowapa, MD@SakditadMD·Oct 21

Excited to join the Clinicals to Exam – Oncology Board Review during #ASH2026 in New Orleans on December 11! Looking forward to strengthening my clinical knowledge, gaining valuable insights, and connecting with fellow hematology/oncology professionals! #HemeOnc #Oncology #MedEd @OncUpdates @OncBrothers @TwoOncDocs #hematology OncologyBrothers.regfox.com/…

TwoOncDocs avatar
TwoOncDocs@TwoOncDocs·Oct 20

C) In the NCCN the preferred 1L therapy for HR-positive, HER2-negative recurrent/metastatic disease is an AI combined with a CDK4/6 inhibitor; among these, the AI + ribociclib combination is specifically designated category 1, based on the OS benefit shown in the MONALEESA trials